Collaboration with Sygnature Discovery in AI for New Drug Design

by Payash Bahuguna | May 10, 2022 | PR

Iktok and Sygnature Discovery announce their collaboration in Artificial Intelligence for de novo  drug design. Under the 3-year agreement, Sygnature will deploy Iktos’ de novo generative design software Makya™, which will be used by Sygnature scientists to facilitate...

Iktos and Teijin Pharma to Co-Develop New Technology for Small Molecule Drug Discovery

by Payash Bahuguna | Apr 5, 2022 | PR

Iktos and Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business that provides comprehensive healthcare services to improve the quality of life, announce a strategic collaboration agreement in Artificial Intelligence for new drug design....

Collaboration with Astrogen to Use AI Platform

by Payash Bahuguna | Jan 5, 2022 | PR

Iktos and Astrogen have entered into a research collaboration agreement aimed at discovery of innovative small molecule pre-clinical drug candidates for Parkinson’s disease. Follow the link for the full press...

Collaboration with The University of Dundee to Use AI for Drug Design and Retrosyntheis

by Payash Bahuguna | Dec 25, 2021 | PR

Under the agreement, Iktos will apply its de novo ligand and structure-based generative modelling technologies, its AI-based retrosynthesis analysis and planning tool Spaya™, and know-how complementing DDU’s drug discovery capabilities to expedite the identification...

Collaboration in AI for new drug design with Jiangsu Hengrui Pharmaceuticals Co., Ltd.

by Payash Bahuguna | Dec 8, 2021 | PR

Iktos announces deployment of our AI for drug design software Makya™ by Jiangsu Hengrui Pharmaceuticals Co., Ltd. Follow the link for the full press...

Collaboration with Chiesi Group to use AI Software Makya™ for new drug design

by Payash Bahuguna | Dec 2, 2021 | PR

Iktos announces deployment of our AI for drug design software Makya™ by Chiesi Group. Follow the link for the full press...